[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352007-105":59,"doc-detail-352007-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-role-of-ulk3-in-cancer-progression-a-pan-cancer-bioinformatics-analysis-integrated-with-experimental-validation-in-prostate-cancer","The Role of ULK3 in Cancer Progression - A Pan-Cancer Bioinformatics Analysis Integrated with Experimental Validation in Prostate Cancer","","Unc-51-like kinase 3 (ULK3) is a serine/threonine kinase whose aberrant expression is increasingly connected with tumor initiation and malignant progression, yet its precise function remains insufficiently defined. The study integrates TCGA, GTEx, and CPTAC multi-omics to profile ULK3 transcript and protein expression across 33 cancer types, assessing alterations, prognosis, splicing, enrichment, stemness, immune infiltration, and immunotherapy biomarkers. Parallel experiments in prostate cancer PC-3 cells evaluate ULK3 roles in localization, migration, and proliferation, and use CMap screening with docking to propose ULK3 activators. Results link ULK3 upregulation to poor survival, cancer stemness, immunosuppression, and RNA dysregulation, supporting biomarker and immunotherapy response potential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-role-of-ulk3-in-cancer-progression-a-pan-cancer-bioinformatics-analysis-integrated-with-experimental-validation-in-prostate-cancer/352007/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-role-of-ulk3-in-cancer-progression-a-pan-cancer-bioinformatics-analysis-integrated-with-experimental-validation-in-prostate-cancer/352007.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What datasets and analyses are used to study ULK3 pan-cancer expression and function?","Question",{"text":112,"@type":113},"The work integrates multi-omics data from TCGA, GTEx, and CPTAC and evaluates ULK3 expression at both transcript and protein levels, together with genomic alterations, prognostic significance, alternative splicing, pathway enrichment, tumor stemness, immune infiltration, and immunotherapy-related biomarkers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does ULK3 expression relate to patient outcomes across cancer types?",{"text":117,"@type":113},"ULK3 is upregulated in 13 cancer types and downregulated in selected others, and high ULK3 expression is associated with poor overall survival in multiple cancers including Adrenocortical Carcinoma, Kidney Renal Clear Cell Carcinoma, and Skin Cutaneous Melanoma.",{"name":119,"@type":110,"acceptedAnswer":120},"What experimental evidence supports ULK3’s role in prostate cancer cells?",{"text":121,"@type":113},"In PC-3 cells, the study uses cellular localization analysis, wound-healing assays, and MTT assays to show that ULK3 overexpression promotes proliferation and migration. Connectivity Map screening and molecular docking further identify Cephaeline as a putative ULK3 activator.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352007,1790872294,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nThe Role of ULK3 in Cancer Progression: A Pan-Cancer Bioinformatics Analysis Integrated with Experimental Validation in Prostate Cancer  \nYangyang Han 1,2,3, Mengqi Zhang 1, Mannizire Rehemujiang 1, Xintong Li 1, Yimin Liu 1, Niuniu Zhang 1, Meng Sun 1, Yunbo Zhang 1, Ayshamgul Hasim 2,4 and Mengjia Li 1,2, *  \nAcademic Editor: Stergios Boussios  \nReceived: 6 June 2026  \nRevised: 26 June 2026  \nAccepted: 29 June 2026  \nPublished: 5 July 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Biology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830017, China; [yyhan@xjmu.edu.cn](yyhan@xjmu.edu.cn) (Y.H.); [13894343612@163.com](13894343612@163.com) (M.Z.); [18999960754@163.com](18999960754@163.com) (M.R.); [15098373960@163.com](15098373960@163.com) (X.L.); [18199840012@163.com](18199840012@163.com) (Y.L.); [13899065367@163.com](13899065367@163.com) (N.Z.); [sm199901@163.com](sm199901@163.com) (M.S.); [18768900024@163.com](18768900024@163.com) (Y.Z.)  \n2 Xinjiang Key Laboratory of Molecular Biology for Endemic Diseases, Xinjiang Medical University, Urumqi 830017, China; [axiangu@xjmu.edu.cn](axiangu@xjmu.edu.cn)  \n3 Key Laboratory of High Incidence Disease Research in Xingjiang, Xinjiang Medical University, Ministry of Education, Urumqi 830017, China  \n4 Department of Basic Medicine, Xinjiang Medical University, Urumqi 830017, China  \n* [Correspondence: mengjiali@xjmu.edu.cn](Correspondence: mengjiali@xjmu.edu.cn)  \nAbstract  \nUnc-51-like kinase 3 (ULK3) is a key member of the ULK serine/threonine kinase family. Aberrant ULK3 expression has been increasingly linked to tumorigenesis and malignant progression in multiple cancer types. However, the precise role of ULK3 in tumor initiation and progression remains incompletely understood. Leveraging integrated multi-omics data from The Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression (GTEx) project, and the Clinical Proteomic Tumor Analysis Consortium (CPTAC), we systematically characterized the expression of ULK3 at both the transcript and protein levels across 33 cancer types. We also evaluated genomic alterations, prognostic significance, alternative splicing, pathway enrichment, tumor stemness, immune infiltration, and immunotherapy-related biomarkers. In parallel, we investigated the function of ULK3 in prostate cancer PC-3 cells using cellular localization analysis, wound-healing assays, and MTT assays. We further applied Connectivity Map (CMap) screening and molecular docking to identify candidate ULK3 activators. ULK3 was significantly upregulated in 13 cancer types, including Bladder Urothelial Carcinoma, Breast Invasive Carcinoma, and Lung Adenocarcinoma. In contrast, ULK3 was downregulated in Cholangiocarcinoma and Head and Neck Squamous Cell Carcinoma. High ULK3 expression was associated with poor overall survival in Adrenocortical Carcinoma, Kidney Renal Clear Cell Carcinoma, and Skin Cutaneous Melanoma. Copy number amplification contributed to ULK3 overexpression. A recurrent A206V missense mutation was detected in the protein kinase (Pkinase) domain. Genes co-expressed with ULK3 were enriched in RNA splicing, methylation, oxidative phosphorylation, and energy metabolism. ULK3 expression showed positive correlations with tumor stemness indices and m1A/m5C/m6A RNA modification regulators. From an immunological perspective, high ULK3 expression was associated with lower Immune Score, increased M2 macrophage infiltration, and co-expression of PD-L1, CTLA4, and LAG3 in most cancers. ULK3 expression was also correlated with Tumor Mutational Burden in Kidney Renal Clear Cell Carcinoma and Rectum Adenocarcinoma. In addition, ULK3 expression was associated with Microsatellite Instability in Brain Lower Grade Glioma, Lung Adenocarcinoma, and Uterine Corpus Endometr","cbCaimtTMs91m1Wk","https://ap.wps.com/l/cbCaimtTMs91m1Wk","pdf",41657694,35,"English","# Introduction\n## Cancer burden and biomarker need\n## ULK kinase family and ULK3 context\n# Materials and Methods\n## Multi-omics integration and analyses\n## Experimental validation in prostate cancer PC-3 cells\n## Candidate activator identification (CMap and docking)\n# Results\n## ULK3 expression patterns across cancer types\n## Genomic alterations and clinical associations\n## Pathway, stemness, and RNA modification correlations\n## Immune infiltration and immunotherapy marker relationships\n## Cellular effects and candidate activators\n# Discussion\n## ULK3 as diagnostic/prognostic and immunotherapy biomarker","[{\"question\":\"What datasets and analyses are used to study ULK3 pan-cancer expression and function?\",\"answer\":\"The work integrates multi-omics data from TCGA, GTEx, and CPTAC and evaluates ULK3 expression at both transcript and protein levels, together with genomic alterations, prognostic significance, alternative splicing, pathway enrichment, tumor stemness, immune infiltration, and immunotherapy-related biomarkers.\"},{\"question\":\"How does ULK3 expression relate to patient outcomes across cancer types?\",\"answer\":\"ULK3 is upregulated in 13 cancer types and downregulated in selected others, and high ULK3 expression is associated with poor overall survival in multiple cancers including Adrenocortical Carcinoma, Kidney Renal Clear Cell Carcinoma, and Skin Cutaneous Melanoma.\"},{\"question\":\"What experimental evidence supports ULK3’s role in prostate cancer cells?\",\"answer\":\"In PC-3 cells, the study uses cellular localization analysis, wound-healing assays, and MTT assays to show that ULK3 overexpression promotes proliferation and migration. Connectivity Map screening and molecular docking further identify Cephaeline as a putative ULK3 activator.\"}]","The Role of ULK3 in Cancer Progression - A Pan-Cancer Bioinformatics Analysis Integrated with Experimental Validation in Prostate Cancer | PDF",1790096912,88,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c31b80c6ba7b8d300e6875e3ec851fa6.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e10f38886d3907109f0f197033f02c99.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e823055d68489056233c70422ef1c4ef.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72cbca68cd7662d125661cda4e9d12ae.webp",980,1385]